Fortimedix Surgical completes €11M funding round to support launch of world’s first single-port surgery solution

Fortimedix Surgical today announced the completion of an €11M Series A funding round. The round was led by Chemelot Ventures, a Netherlands-based, venture capital firm focused on investing in smart materials and life sciences, along with participation from all existing shareholders. The company will use these funds to support the U.S. and European launch of FMX314, the world’s first single-port surgery solution that is compatible with a standard 15mm trocar for use in minimally invasive abdominal laparoscopic surgery.

“We are proud to partner with Fortimedix Surgical as it launches FMX314, which we believe can deliver on the promise of single-port laparoscopic surgery,” commented Casper Bruens, Managing Director of Chemelot Ventures. “Since 2004 our firm has been involved with Fortimedix, a global leader in the field of endovascular stents, the company from which Fortimedix Surgical emerged in 2012. We have gained tremendous trust in the company’s leadership and are confident Fortimedix Surgical will achieve the ambitious commercial milestones for FMX314 as planned.”

FMX314 promises fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis. Emulating conventional, multi-port laparoscopy makes FMX314 easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach.

“We are excited to have Chemelot Ventures as an investment partner in our company, as we rapidly advance to commercialize FMX314 in key markets around the world,” said Mr. Wout Bijker, CEO of Fortimedix Surgical. “Following the recent 510(k) FDA Clearance in the U.S. and CE Mark Approval in Europe, this funding round represents another significant achievement that further enables us to offer the innovative FMX314 Surgical Platform to patients and healthcare communities around the world.”

FMX314 will be formally launched in the U.S. during the American College of Surgeons (ACS) Clinical Congress, taking place October 16 – 20, 2016 in Washington, D.C., where Fortimedix Surgical will be located at booth #1139. The European commercial launch is planned for 2017.